

ELENCO PUBBLICAZIONI DEGLI ULTIMI 5 ANNI

1. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di RF, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, Perrone G, Brioli A, Petrucci A, Motta MR, Rizzi S, Buttignol S, Foà R, et.al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. **Lancet** 376:2075, 2010.
2. Perosa F, Prete M, Racanelli V, Dammacco F: CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. **J Intern Med** 267:260, 2010.
3. Perosa F, Vicenti C, Racanelli V, Leone P, Valentini G, Dammacco F: The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). **Clin Immunol** 137:60, 2010.
4. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F: Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. **Blood** 115:1185, 2010.
5. Perosa F, Vicenti C, Racanelli V, Leone P, Valentini G, Dammacco F: The major antigenic determinant of CENP-A shows antigenic and immunogenic homology with the transcription factor forkhead box E3 (FOXE3). Serendipity or functional significance? **Ann Rheum Dis** 68:160, 2009.
6. Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, De P, V, Dammacco F: Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes. **J Immunol** 182:416, 2009.
7. Perosa F, Minoia C, Favoino E, Prete M, Dammacco F: Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. **Blood Cells Mol Dis** 42:71, 2009.
8. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F: Rheumatic disorders as paraneoplastic syndromes. **Autoimmun Rev** 7:352, 2008.
9. Merchionne F, Perosa F, Dammacco F: New therapies in multiple myeloma. **Clin Exp Med** 7:83, 2007.
10. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F: Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. **J Immunol** 179:7967, 2007.
11. Perosa F, Favoino E, Caragnano MA, Dammacco F: Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. **Blood** 107:1070, 2006.
12. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F: CD20: A target antigen for immunotherapy of autoimmune diseases. **Autoimmun Rev** 4:526, 2005.